Publication:
Pediatric-onset chronic inflammatory demyelinating polyneuropathy: A multicenter study

dc.contributor.authorUzan, Gamze Sarıkaya
dc.contributor.authorVural, Atay
dc.contributor.authorYüksel, Deniz
dc.contributor.authorAksoy, Erhan
dc.contributor.authorÖztoprak, Ülkühan
dc.contributor.authorCanpolat, Mehmet
dc.contributor.authorÖztürk, Selcan
dc.contributor.authorYıldırım, Çelebi
dc.contributor.authorGüleç, Ayten
dc.contributor.authorPer, Hüseyin
dc.contributor.authorGümüş, Hakan
dc.contributor.authorOkuyaz, Çetin
dc.contributor.authorDirek, Meltem Çobanoğulları
dc.contributor.authorKosmür, Mustafa
dc.contributor.authorÜnalp, Aycan
dc.contributor.authorYılmaz, Ünsal
dc.contributor.authorBektas, Ömer
dc.contributor.authorTeber, Serap
dc.contributor.authorAliyeva, Nargiz
dc.contributor.authorDündar, Nihal Olgaç
dc.contributor.authorGençpınar, Pınar
dc.contributor.authorGürkaş, Esra
dc.contributor.authorYılmaz, Sanem Keskin
dc.contributor.authorKanmaz, Seda
dc.contributor.authorTekgtil, Hasan
dc.contributor.authorAksoy, Ayşe
dc.contributor.authorTuncer, Gökcen Öz
dc.contributor.authorArslan, Elif Acar
dc.contributor.authorTosun, Ayşe
dc.contributor.authorKızılırmak, Ali Burak
dc.contributor.authorYousefi, Mohammadreza
dc.contributor.authorÜnay, Bülent
dc.contributor.authorKurul, Semra Hiz
dc.contributor.authorYis, Uluç
dc.contributor.buuauthorAyanoğlu, Müge
dc.contributor.buuauthorBodur, Muhittin
dc.contributor.buuauthorBODUR, MUHİTTİN
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.contributor.orcid0000-0002-2588-8195
dc.contributor.researcheridJAN-9435-2023
dc.contributor.researcheridEKU-8347-2022
dc.date.accessioned2024-12-04T05:49:48Z
dc.date.available2024-12-04T05:49:48Z
dc.date.issued2023-05-26
dc.description.abstractBackground: To evaluate the clinical features, demographic features, and treatment modalities of pediatric-onset chronic inflammatory demyelinating polyneuropathy (CIDP) in Turkey. Methods: The clinical data of patients between January 2010 and December 2021 were reviewed retrospectively. The patients were evaluated according to the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society Guideline on the management of CIDP (2021). In addition, patients with typical CIDP were divided into two groups according to the first-line treatment modalities (group 1: IVIg only, group 2: IVIg + steroid). The patients were further divided into two separate groups based on their magnetic resonance imaging (MRI) characteristics. Results: A total of 43 patients, 22 (51.2%) males and 21 (48.8%) females, were included in the study. There was a significant difference between pretreatment and post-treatment modified Rankin scale (mRS) scores (P < 0.05) of all patients. First-line treatments include intravenous immunoglobulin (IVIg) (n = 19, 4 4.2%), IVIg + steroids (n = 20, 46.5%), steroids (n = 1, 2.3%), IVIg + steroids + plasmapheresis (n = 1, 2.3%), and IVIg + plasmapheresis (n = 1, 2.3%). Alternative agent therapy consisted of azathioprine (n = 5), rituximab (n = 1), and azathioprine + mycophenolate mofetil + methotrexate (n = 1). There was no difference between the pretreatment and post-treatment mRS scores of groups 1 and 2 (P > 0.05); however, a significant decrease was found in the mRS scores of both groups with treatment (P < 0.05). The patients with abnormal MRI had significantly higher pretreatment mRS scores compared with the group with normal MRI (P < 0.05). Conclusions: This multicenter study demonstrated that first-line immunotherapy modalities (IVIg vs IVIg + steroids) had equal efficacy for the treatment of patients with CIDP. We also determined that MRI features might be associated with profound clinical features, but did not affect treatment response.
dc.identifier.doi10.1016/j.pediatrneurol.2023.04.018
dc.identifier.endpage10
dc.identifier.issn0887-8994
dc.identifier.startpage3
dc.identifier.urihttps://doi.org/10.1016/j.pediatrneurol.2023.04.018
dc.identifier.urihttps://hdl.handle.net/11452/48852
dc.identifier.volume145
dc.identifier.wos001026994200001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.journalPediatric Neurology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.relation.tubitak118S397
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPolyradiculoneuropathy
dc.subjectFeatures
dc.subjectImmunotherapy
dc.subjectDiagnosis
dc.subjectChildren
dc.subjectNerves
dc.subjectCidp
dc.subjectMri
dc.subjectChronic inflammatory demyelinating
dc.subjectPolyneuropathy
dc.subjectChildhood
dc.subjectImmunotherapy
dc.subjectIvig
dc.subjectSteroids
dc.subjectNeurofascin antibodies
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectClinical neurology
dc.subjectPediatrics
dc.subjectNeurosciences & neurology
dc.titlePediatric-onset chronic inflammatory demyelinating polyneuropathy: A multicenter study
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
relation.isAuthorOfPublication6a7d0ca4-dd18-4890-86fa-1b5a7bd0c4f1
relation.isAuthorOfPublication.latestForDiscovery6a7d0ca4-dd18-4890-86fa-1b5a7bd0c4f1

Files

Collections